NEUCHATEL, Switzerland–(BUSINESS WIRE)–Swiss Advanced Vision (SAV-IOL) heeft de lancering aangekondigd van Harmonis, een aanpasbare intraoculaire lens (IOL) met geavanceerde EDOF (extended depth of focus) optische technologie voor cataractchirurgie. Voor het eerst zullen oogartsen een webgebaseerde configurator kunnen gebruiken om de beste optische parameters van de lens te definiëren die passen bij het gewenste visuele resultaat voorafgaand aan de operatie. SAV-IOL zal Harmonis op de markt b
Author: Business Wire
Swiss Advanced Vision lance Harmonis, la première lentille intraoculaire à profondeur de champ étendue personnalisable
NEUCHÂTEL, Suisse–(BUSINESS WIRE)–Swiss Advanced Vision (SAV-IOL) vient d’annoncer le lancement d’Harmonis, une lentille intraoculaire personnalisable équipée d’une technologie optique avancée à profondeur de champ étendue pour l’opération de la cataracte. Pour la toute première fois, les ophtalmologues seront en mesure d’utiliser un configurateur en ligne pour définir les paramètres optiques optimaux de la lentille en accord avec le résultat visuel escompté avant l’intervention chirurgicale.
Swiss Advanced Vision präsentiert Harmonis – die erste anpassbare EDOF-Intraokularlinse für die Kataraktchirurgie
NEUCHATEL, Schweiz–(BUSINESS WIRE)–Swiss Advanced Vision (SAV-IOL) meldet die Einführung von Harmonis, einer anpassbaren Intraokularlinse (IOL) für die Kataraktchirurgie, die mit der hochmodernen optischen EDOF (Extended Depth of Focus)-Technologie ausgestattet ist. Damit haben Ophthalmologen zum ersten Mal die Möglichkeit, vor der Operation die optischen Parameter der Linse mithilfe eines webbasierten Konfigurators so festzulegen, dass sie dem angestrebten Sehergebnis am besten entsprechen.
Swiss Advanced Vision Launches Harmonis – The First Customizable EDOF IOL for Cataract Surgery
NEUCHATEL, Switzerland–(BUSINESS WIRE)–Swiss Advanced Vision launches Harmonis, the first customizable intraocular lens with advanced EDOF technology for cataract surgery.
Gary Winer Joins LENSAR, Inc. Board of Directors
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. announces global healthcare senior executive Gary Winer has joined the company’s board of directors.
Global Glass Lens Market 2018-2022| Progressive Glass Lenses Segment Dominates the Global Market| Technavio
LONDON–(BUSINESS WIRE)–#Research–According to the latest market research report by Technavio, the global glass lens market is expected to accelerate at a CAGR of around 4% until 2022.
Mati Therapeutics Interim Phase II Nepafenac Clinical Trial Results Signal Significant Post-op Pain Reduction in Cataract Surgery Patients
AUSTIN, Texas–(BUSINESS WIRE)–Mati Therapeutics Inc. (“Mati”) announced that it has completed a planned interim analysis of an ongoing Phase II clinical trial evaluating the safety and efficacy of nepafenac delivered in Mati’s proprietary Evolute® sustained ocular drug delivery platform. The trial is a multi-center, randomized, masked evaluation of nepafenac vs. placebo in 75 patients undergoing cataract surgery. The primary endpoint is to evaluate pain and the secondary endpoint is to evalua
Second Sight Appoints Pat Ryan Chief Operating Officer
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, announced today that Pat Ryan has been appointed Chief Operating Officer, effective immediately. In this newly created role, Mr. Ryan will assume responsibility for Research & Development, Manufacturing, Planning & Ma
2020 On-site appoints Alexis McLaughlin as Chief Executive Officer, Closes Over $5MM in Series B Financing and Named to the Inc. 5000
BOSTON–(BUSINESS WIRE)–#HR–2020 On-site (2020), America’s leading provider of on-site vision care for businesses and schools, serving over 450 leading employers, announced this morning the appointment of Alexis McLaughlin as 2020’s new Chief Executive Officer. McLaughlin will also join 2020’s Board of Directors. Most recently, McLaughlin was SVP/General Manager of Retail Licensed Brands at Luxottica Retail, where she was responsible for $500MM in revenue across 1,000 stores in North America. In h
Horizon Pharma plc Completes Enrollment of Confirmatory Phase 3 Trial of Teprotumumab Ahead of Schedule
DUBLIN–(BUSINESS WIRE)–Horizon Pharma plc (NASDAQ:HZNP) announced the early completion of enrollment for the confirmatory Phase 3 trial of teprotumumab in patients living with moderate-to-severe active thyroid eye disease (TED). The study (NCT03298867 and EudraCT 2017-002763-18) enrolled 83 patients at 13 sites across the United States, Germany and Italy. Topline results are expected in the second quarter of 2019. “Our success in rapidly enrolling this trial speaks to the significant unmet ne
Aura Biosciences Boosts Finance Team with Two Key Appointments, Preparing to Move Into Late-Stage Clinical Development in Ocular Melanoma
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences has boosted its finance team with two key appointments, Chief Financial Officer Julie Feder and VP of Finance Kylie Reynolds.
BioTime Closes $43.2 Million AgeX Share Sale Transaction With Juvenescence
ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it has closed the previously announced transaction with Juvenescence Limited, a global l…
PolyActiva Commences Its First Phase I Clinical Trial with Potential to Improve Daily Lives of Millions of Glaucoma Patients
MELBOURNE, Australia–(BUSINESS WIRE)–Revolutionary new glaucoma treatment, which could remove need for eye drop use, enters clinical trials with USD$12m venture capital-backing.
NovaBay Pharmaceuticals to Present at H.C. Wainwright 20th Annual Global Investment Conference on September 6
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces that management is scheduled to present a corporate overview at the H.C. Wainwright 20th Annual Global Investment Conference on Thursday, September 6, 2018 at 2:35 p.m. Eastern time (5:35 p.m. Pacific time). The conference is being held at the St. Regis New York in New York City. A live webc
Aerpio Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC
CINCINNATI–(BUSINESS WIRE)–Aerpio Pharmaceuticals, Inc. (Nasdaq:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that Chief Executive Officer, Stephen Hoffman, M.D., Ph.D., will present at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, on Thursday, September 6, 2018 at 10:00 a.m. Eastern Time in New York, NY. Dr. Hoffman will provide a corporate overview and b
Montecito Acquires Flagship Ophthalmology Medical Office Building in Arizona
NASHVILLE, Tenn.–(BUSINESS WIRE)–Montecito Medical Real Estate, the nation’s top privately held buyer of medical office properties throughout the U.S., has acquired the primary office building of one of Arizona’s leading ophthalmology practices. The Retinal Consultants of Arizona and Retinal Research Institute Medical Office Building in North Phoenix serves as the headquarters for Retinal Consultants of Arizona (RCA), which maintains 35 locations across Arizona. Established in 1980, RCA has g
Children in Phoenix Receive Free Comprehensive Eye Exams and Prescription Glasses as Part of Back-to-School Public Health Event
PHOENIX–(BUSINESS WIRE)–Phoenix-area children today received free comprehensive eye exams and glasses donations as part of a back-to-school eye-health event.
Children in Phoenix Receive Free Comprehensive Eye Exams and Prescription Glasses as Part of Back-to-School Public Health Event
PHOENIX–(BUSINESS WIRE)–Phoenix-area children today received free comprehensive eye exams and glasses donations as part of a back-to-school eye-health event.
Kala Pharmaceuticals to Present at Upcoming Investor Conferences
WALTHAM, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, today announced t…
Global Optical Coherence Tomography for Ophthalmology Market 2018-2022| Conventional OCT Systems Dominates the Global Market| Technavio
LONDON–(BUSINESS WIRE)–#MedicalImaging–Technavio market research analysts expect the global optical coherence tomography for ophthalmology market to grow at a CAGR of almost 7% until 2022.